Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in North America, Europe and Israel or involving organisations from these countries.

Total search results: 6685 | Ordered by Date (descending)
1 2 3 ... 65 66 67  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
CRISPR Therapeutics–SEVERAL: investment, 201911 public offering up to $315.25m with 4.25m+637.5k common shares at $64.5/share 2019-11-19
Bluebird Bio–Forty Seven: gene therapy, 201911– collab research using Ab-based conditioing regimen with LVV HSC gene therapy 2019-11-12
Celgene–Editas Medicine: T cell therapy, 201911– collab expansion T cell medicines for cancer + autoimmune diseases incl $70m milestone payment 2019-11-12
Immatics–Genedata: bioinformatics, 201911– license to Genedata Biologics for use with Xceptor TCR discovery + engineering platform 2019-11-12
Clear Genetics–Invitae: investment, 201911 acquisition $50m with $25m cash + $25m shares of Clear Genetics by Invitae 2019-11-11
Expedeon–Abcam: investment, 201911– acquisition €120m cash of immunology + proteomics business of Expedeon by Abcam ANNOUNCED 2019-11-11
eGenesis–Alta Partners: investment, 201911 financing round Series B totalling $100m incl existing + co-investor Alta Partners 2019-11-07
eGenesis–ARCH Venture: investment, 201911 financing round Series B totalling $100m incl existing + co-investor ARCH Venture Partners 2019-11-07
eGenesis–Bayer: investment, 201911 financing round Series B totalling $100m incl new + co-investor Leaps by Bayer 2019-11-07
eGenesis–Biomatics Capital: investment, 201911 financing round Series B totalling $100m incl existing + co-investor Biomatics Capital 2019-11-07
eGenesis–Fresenius: investment, 201911 financing round Series B totalling $100m incl lead investor Fresenius Medical Care Ventures 2019-11-07
eGenesis–Khosla Ventures: investment, 201911 financing round Series B totalling $100m incl existing + co-investor Khosla Ventures 2019-11-07
eGenesis–SEVERAL: investment, 201911 financing round Series B $100m led by Fresenius Medical Care Ventures 2019-11-07
eGenesis–Wellington Partners: investment, 201911 financing round Series B totalling $100m incl new + co-investor Wellington Partners 2019-11-07
Owlstone–Thermo Fisher: mass spectrometry, 201911– collab integration of Q Exactive GC Hybrid Quad-Orbitrap MS into Breath Biopsy platform 2019-11-07
Argenx–SEVERAL: investment, 201911 global offering $557m with 4.6m ordinary shares incl in the form of ADSs 2019-11-06
Artios Pharma–Univ Texas: ATR inhibitors, 201911– license excl ww to small-molecula ATR inhibitor programme from MD Anderson + ShangPharma Innovation 2019-11-06
Greenough–KDM Communications: investment, 201911 merger combination to provide transatlantic PR services 2019-11-06
OTHER–Ervaxx: cancer immunotherapy, 201911 collab existent strategic r+d partnership with undisclosed leading global pharma company 2019-11-06
Rentschler–General Electric: single-use bioreactor, 201911–202006 supply Xcellerex XDR-500 bioreactor for Rentschler facility in Milford, MA 2019-11-06
Pieris–BVF Partners: investment, 201911 private placement totalling $32m incl existing + lead investor BVF Partners 2019-11-04
Pieris–SEVERAL: investment, 201911 private placement $32m w 9.015m units (shares + warrants) at $3.55/unit led by BVF Partners 2019-11-04
Fitbit–Alphabet: investment, 201911– acquisition of Fibit Inc by Google LLC for $7.35/share in cash valuing Fibtit at $2.1b ANNOUNCED 2019-11-01
BeiGene–Amgen: cancer drugs, 201910– collab strategic alliance incl Xgeva + Kyprolis + Blincyto + 20 other assets dev + commerc in China 2019-10-31
BeiGene–Amgen: investment, 201910 acquisition 20.5% stake in BeiGene for $2.7b in cash by Amgen in connnection w strategic alliance 2019-10-31
Gyros–Mesa Labs: investment, 201910 acquisition $180m in cash of Gyros Protein Technologies Holding AB by Mesa Laboratories Inc 2019-10-31
Roivant–Sumitomo: investment, 201910 acquisition 10% stake in Roivant by Sumitomo Dainippon Pharma in connection w strategic alliance 2019-10-31
Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Altavant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance 2019-10-31
Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Enzyvant Therapeutics by Sumitomo Dainippon Pharma as part of strategic alliance 2019-10-31
Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Myovant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance 2019-10-31
Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Spirovant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance 2019-10-31
Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Urovant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance 2019-10-31
Sumitomo–Roivant: drug development, 201910– collab strategic alliance $3b upfront incl transfer of 5 vants to Sumitomo Dainippon Pharma 2019-10-31
Tmunity Therapeutics–American Cancer Society: investment, 201910 financing round Series B totalling $75m incl co-investor BrightEdge fund of ACS 2019-10-31
Tmunity Therapeutics–Andreessen Horowitz: investment, 201910 financing round Series B totalling $75m incl lead investor Andreessen Horowitz 2019-10-31
Tmunity Therapeutics–Be The Match: investment, 201910 financing round Series B totalling $75m incl co-investor Be The Match BioTherapies 2019-10-31
Tmunity Therapeutics–Gilead Sciences: investment, 201910 financing round Series B totalling $75m incl co-investor Gilead Sciences 2019-10-31
Tmunity Therapeutics–Sam Brown: public relations, 201910 service existent by Sam Brown Inc 2019-10-31
Tmunity Therapeutics–SEVERAL: investment, 201910 financing round Series B $75m led by Andreessen Horowitz 2019-10-31
Tmunity Therapeutics–Univ Pennsylvania: investment, 201910 financing round Series B totalling $75m incl co-investor Univ Pennsylvania 2019-10-31
Tmunity Therapeutics–Westlake Village BioPartners: investment, 201910 financing round Series B totalling $75m incl co-investor Westlake Village BP 2019-10-31
genOway–Institut Pasteur: transgenic anmials, 201910– license extension from IP + Cellectis to genOway to take legal actions against infringement 2019-10-30
Disc Medicine–AbbVie: therapeutics antibodies, 201910– license €na ww excl to series of hemojuvelin antagonist MAbs from AbbVie 2019-10-29
Disc Medicine–Access Industries: investment, 201910 financing round Series A totalling $50m incl new + co-investor Access Biotechnology 2019-10-29
Disc Medicine–Atlas Venture: investment, 201910 financing round Series A totalling $50m incl existing + co-investor Atlas Venture 2019-10-29
Disc Medicine–Novo Group: investment, 201910 financing round Series A totalling $50m incl new + lead investor Novo Holdings A/S 2019-10-29
Disc Medicine–SEVERAL: investment, 201910 financing round Series A $50m led by Novo Holdings A/S 2019-10-29
Phathom Pharmaceuticals–Sam Brown: public relations, 201910 service existent by Sam Brown Inc 2019-10-29
Phathom Pharmaceuticals–SEVERAL: investment, 201910 IPO $181.7m+$27.2m with 9.56m+1.43m shares common stock at $19/share at Nasdaq Global Select 2019-10-29
TherapeuticsMD–SEVERAL: investment, 201910 underwritten public offering $82.225m net $77m with 29.9m shares common stock at $2.75/share 2019-10-29
Centogene–SEVERAL: investment, 201910–201911 IPO $56m+$8.4m with 4m+600k comon shares at $14/share at Nasdaq Global Market 2019-10-28
i-Dositecno–SP Industries: investment, 201910 acquisition of assets of i-Dositecno by SP Industries 2019-10-28
PierianDx–SEVERAL: investment, 201910 financing round Series B $27m co-led by ATW Partners + SJF Ventures 2019-10-28
SMS-Oncology–Cato Research: investment, 201910 merger €na 2019-10-28
OpGen–SEVERAL: investment, 201910 underwritten public offering $9.4m 2019-10-23
Brii Biosciences–Qpex Biopharma: antibiotics, 201910– collab developm + comercialisation in Greater China 2019-10-22
Encycle Therapeutics–Zealand Pharma: investment, 201910 acquisition of Encycle Therapeutics for up to $80m 2019-10-22
MCG Motion Capture–Akampion: public relations, 201910 service existent by Akampion 2019-10-22
MCG Motion Capture–Biotech Alliances International: investment banking, 201910– service excl for planned $15m Series A Round of MCG 2019-10-22
MCG Motion Capture–SEVERAL: investment, 201910– PLANNED financing round Series A $15m 2019-10-22
Arcutis Biotherapeutics–Bain Capital: investment, 201910 financing round Series C totalling $94.5m incl existing + co-investor Bain Capital LS 2019-10-21
Arcutis Biotherapeutics–BlackRock: investment, 201910 financing round Series C totalling $94.5m incl new + co-investor funds managed by BlackRock 2019-10-21
Arcutis Biotherapeutics–Frazier: investment, 201910 financing round Series C totalling $94.5m incl existing + co-investor Frazier Healthcare Partners 2019-10-21
Arcutis Biotherapeutics–Goldman Sachs: investment, 201910 financing round Series C totalling $94.5m incl new + co-investor Goldman Sachs 2019-10-21
Arcutis Biotherapeutics–HBM: investment, 201910 financing round Series C totalling $94.5m incl new + lead investor HBM Healthcare Investments 2019-10-21
Arcutis Biotherapeutics–Nan Fung: investment, 201910 financing round Series C totalling $94.5m incl new + co-investor Pivotal BioVentures 2019-10-21
Arcutis Biotherapeutics–Omega Advisors: investment, 201910 financing round Series C totalling $94.5m incl new + co-investor Omega Funds 2019-10-21
Arcutis Biotherapeutics–OrbiMed: investment, 201910 financing round Series C totalling $94.5m incl existing + co-investor OrbiMed 2019-10-21
Arcutis Biotherapeutics–RA Capital Management: investment, 201910 financing round Series C totalling $94.5m incl existing + co-investor RA Capital 2019-10-21
Arcutis Biotherapeutics–SEVERAL: investment, 201910 financing round Series C $94.5m led by HBM Healthcare Investments 2019-10-21
Arcutis Biotherapeutics–Vivo Capital: investment, 201910 financing round Series C totalling $94.5m incl new + co-investor Vivo Capital 2019-10-21
Bavarian Nordic–GSK: vaccines, 201910 acquisition up to €796m incl €301m upfront of manufacturing + global rights to Rabipur/RabAvert + Encepur by BN 2019-10-21
Danaher–Sartorius: investment, 201910– acquisition $750m three life science businesses by Sartorius part of regulatory clearance for GE/Danaher deal 2019-10-21
Innate Pharma–SEVERAL: investment, 201910 pirvate placement €22.13m with 4.45m ordinary shares at €4.97/share 2019-10-21
Verseau Therapeutics–20/20 HealthCare Partners: investment, 201910 launch with a total financing of $50m incl investor 20/20 HealthCare Partners 2019-10-21
Verseau Therapeutics–Alexandria Real Estate: investment, 201910 launch with a total financing of $50m incl investor Alexandria Venture Investments 2019-10-21
Verseau Therapeutics–Highlight Capital: investment, 201910 launch with a total financing of $50m incl investor Highlight Capital 2019-10-21
Verseau Therapeutics–InHarv Partners: investment, 201910 launch with a total financing of $50m incl investor InHarv Partners 2019-10-21
Verseau Therapeutics–Mark Foundation: investment, 201910 launch with a total financing of $50m incl The Mark Foundation for Cancer Research 2019-10-21
Verseau Therapeutics–SEVERAL: investment, 201910 launch with $50m financing from 20/20 HealthCare Partners + 3SBio + Alexandria Venture et al 2019-10-21
Verseau Therapeutics–Yonghua Capital: investment, 201910 launch with a total financing of $50m incl investor Yonghua Capital 2019-10-21
Plexium–Column Group: investment, 201910 financing round Series A totalling $28m incl co-lead investor The Column Group 2019-10-17
Plexium–CRV: investment, 201910 financing round Series A totalling $28m incl co-investor CRV 2019-10-17
Plexium–DCVC: investment, 201910 financing round Series A totalling $28m incl co-lead investor DCVC Bio 2019-10-17
Plexium–Little Dog Communications: public relations, 201910 service existent by Little Dog 2019-10-17
Plexium–Merck (DE): investment, 201910 financing round Series A totalling $28m incl co-investor M Ventures 2019-10-17
Plexium–Neotribe Ventures: investment, 201910 financing round Series A totalling $28m incl co-investor Neotribe Ventures 2019-10-17
Plexium–SEVERAL: investment, 201910 financing round Series A $28m co-led by DCVC Bio + The Column Group 2019-10-17
Sofinnova–SEVERAL: investment, 201910 closing €333m of Sofinnova Capital IX fund 2019-10-17
Healx–Atomico: investment, 201910 financing round Series B totalling $56m incl new + lead investor Atomico 2019-10-16
Healx–Global Brain: investment, 201910 financing round Series B totalling $56m incl new + co-investor Global Brain 2019-10-16
Healx–Intel: investment, 201910 financing round Series B totalling $56m incl new + co-investor Intel Capital 2019-10-16
Healx–SEVERAL: investment, 201910 financing round Series B $56m led by new investor Atomico 2019-10-16
Waters–Salesforce: CRM cloud software, 201910– supply Waters to use Sales Cloud Einstein + Service Cloud + Einstein Analytics 2019-10-16
CRISPR Therapeutics–KSQ Therapeutics: CRISPR-based cell therapy, 201910– cross-licensing €na genome editing + CAR-T cell therapy IP 2019-10-15
Editas Medicine–AskBio: AAV technology, 201910– strategic research collab in vivo delivery of genome editing medicines with AAV 2019-10-15
FloDesign Sonics–Merck (DE): investment, 201910 acquisition €na by Merck 2019-10-10
Mission Bio–VSC (US): public relations, 201910 service existent by VSC 2019-10-10
Ra Pharmaceuticals–UCB: investment, 201910– acquisition $2.5b in cash for $48/share incl acquired net cash of $315m ANNOUNCED 2019-10-10
Celmatix–Evotec: drug discovery services, 201910– collab €na developm pre-clinical programs for reproductive women’s health 2019-10-09
1 2 3 ... 65 66 67  next pagenext page



Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 iito 650x76px

» top